Faculty Bibliography

Introduction: Activities of daily living (ADLs) are performed through a sequence of fundamental units of motion, called primitives. We previously observed that during ADLs, one upper extremity (UE) may engage two objects simultaneously, such as turning on a faucet while holding a toothbrush. These dual-object primitives (DOPs) may demand increased neural resources, as they likely entail the simultaneous execution of two motor plans. Skilled movement by the nondominant healthy UE or the paretic UE has also been found to require increased neural activity. We posited that performance of DOPs would exceed the neural resources available to the nondominant or paretic side, reducing their performance on these sides. We also predicted that the frequency of DOP performance by the paretic UE would relate to its degree of motor impairment.
Method(s): We studied 19 right-hand dominant healthy subjects (10M:9F; 62.0 +/- 13.6 years) and 43 premorbidly right-hand dominant stroke subjects (23M:20F; 24L:19R paretic; 57.5 +/- 14.5 years; 5.7 +/- 6.5 years post stroke). We evaluated subjects on the UE Fugl-Meyer Assessment (FMA) and videotaped their performance of a feeding and toothbrushing task. We analyzed the videos to extract the incidence and count of DOP performance by each UE. To control for dominance and paresis, we normalized DOP counts to the total number of primitives performed by the UE. We used two-tailed Fisher's Exact tests to compare the incidence of DOPs performed by each UE, and Spearman's correlation to examine the relationship between FMA score and DOP frequency.
Result(s): In healthy subjects, the incidence of DOPs was lower on the nondominant than dominant side (12/19 vs. 19/19; p<0.01). In stroke subjects, the incidence of DOPs was lower on the paretic than nonparetic side (19/43 vs. 43/43; p<0.01). The laterality of paresis did not affect whether that UE would perform DOPs (11/19 dominant paretic vs. 8/24 nondominant paretic; p=0.132). In stroke subjects, lower FMA scores were related to a lower frequency of DOP performance on their paretic UE (rho=0.368, p=0.015).
Discussion(s): Our results suggest that UE laterality and impairment may impact DOP performance in healthy and stroke subjects, respectively. DOPs were less commonly performed by the nondominant UE and the paretic UE, and worse impairment was associated with lower DOP performance. We speculate that engaging two objects simultaneously requires additional neural resources that are unavailable to the nondominant or injured motor network. It is conceivable that the return of DOP performance by the paretic UE may track with the availability of a recovered neural substrate.

OBJECTIVE:To update a 1996 American Academy of Neurology practice parameter. METHODS:The authors systematically reviewed literature published from January 1991 to March 2020. RESULTS:The long-term (24-60 months) risk of seizure recurrence is possibly higher among adults who have been seizure-free for 2 years and taper antiseizure medications (ASMs) vs those who do not taper ASMs (15% vs 7% per the 1 Class I article addressing this issue). In pediatric patients, there is probably no significant difference in seizure recurrence between those who begin tapering ASMs after 2 years vs 4 years of seizure freedom, and there is insufficient evidence of significant difference in risk of seizure recurrence between those who taper ASMs after 18 months of seizure freedom and those tapering after 24 months. There is insufficient evidence that the rate of seizure recurrence with ASM withdrawal following epilepsy surgery after 1 year of seizure freedom vs after 4 years is not significantly different than maintaining patients on ASMs. An epileptiform EEG in pediatric patients increases the risk of seizure recurrence. ASM withdrawal possibly does not increase the risk of status epilepticus in adults. In seizure-free adults, ASM weaning possibly does not change quality of life. Withdrawal of ASMs at 25% every 10 days to 2 weeks is probably not significantly different from withdrawal at 25% every 2 months in children who are seizure-free in more than 4 years of follow-up. RECOMMENDATIONS/CONCLUSIONS:Fourteen recommendations were developed.

PURPOSE OF REVIEW:Behavioral therapies are proven treatments for many neurologic conditions. However, the COVID-19 pandemic has posed significant challenges for conducting behavioral research. This article aims to (1) highlight the challenges of running behavioral clinical trials during the pandemic, (2) suggest approaches to maximize generalizability of pandemic-era studies, and (3) offer strategies for successful behavioral trials beyond the pandemic. RECENT FINDINGS:Thousands of clinical trials have been impacted by the COVID-19 pandemic, from undergoing protocol revisions to suspension altogether. Furthermore, for ongoing trials, recruitment of diverse populations has suffered, thereby exacerbating existing inequities in clinical research. Patient adherence and retention have been affected by a myriad of pandemic-era restraints, and medical, psychiatric, and other complications from the pandemic have the potential to have long-term effects on pandemic-era study results. In the development of post-pandemic study protocols, attention should be given to designing studies that incorporate successful aspects of pre-pandemic and pandemic-era strategies to (1) broaden recruitment using new techniques, (2) improve access for diverse populations, (3) expand protocols to include virtual and in-person participation, and (4) increase patient adherence and retention.

Purpose of Review/UNASSIGNED:In 2019, over 50 million Americans were expected to use wearables at least monthly. The technologies have varied capabilities, with many designed to monitor health conditions. We present a narrative review to raise awareness of wearable technologies that may be relevant to the field of neurology. We also discuss the implications of these wearables for our patients and briefly discuss issues related to researching new wearable technologies. Recent Findings/UNASSIGNED:There are a variety of wearables for neurologic conditions, e.g., stroke (for potential arrhythmia capture), epilepsy, Parkinson disease, and sleep. Research is being performed to capture the risk of neuropsychiatric relapse. However, data are limited and adherence to these wearables is often poorly studied. Summary/UNASSIGNED:The care of neurology patients may ultimately be improved with the use of wearable technologies. More research needs to examine efficacy and implementation strategies.

Objective/UNASSIGNED:Evaluate whether the benefits of Mindfulness-Based Cognitive Therapy for Migraine (MBCT-M) on headache disability differs among people with episodic and chronic migraine (CM). Methods/UNASSIGNED:This is a planned secondary analysis of a randomized clinical trial. After a 30-day baseline, participants were stratified by episodic (6-14 d/mo) and CM (15-30 d/mo) and randomized to 8 weekly individual sessions of MBCT-M or wait list/treatment as usual (WL/TAU). Primary outcomes (Headache Disability Inventory; Severe Migraine Disability Assessment Scale [scores ≥ 21]) were assessed at months 0, 1, 2, and 4. Mixed models for repeated measures tested moderation with fixed effects of treatment, time, CM, and all interactions. Planned subgroup analyses evaluated treatment*time in episodic and CM. Results/UNASSIGNED:= 0.268). Conclusions/UNASSIGNED:MBCT-M is a promising treatment for reducing headache-related disability, with greater benefits in episodic than CM. Trial Registration Information/UNASSIGNED:ClinicalTrials.gov Identifier: NCT02443519. Classification of Evidence/UNASSIGNED:This study provides Class III evidence that MBCT-M reduces headache disability to a greater extent in people with episodic than CM.

Batten disease, also known as neuronal ceroid lipofuscinosis, refers to a diverse group of 13 hereditary inborn errors of metabolism resulting in the abnormal accumulation of autofluorescent storage material in lysosomes leading to neurodegeneration, typically with associated intractable epilepsy, behavioral dysregulation, cognitive, motor, language and visual decline, as well as a shortened life expectancy [1]. Assessment of disease progression within this population is fraught with difficulty because individuals may have limited attention or cooperation affecting compliance with requested tasks, or have visual impairment reducing options for methods of assessment. Further, language and cognitive assessments have been designed to assess typically developing individuals based on specific age limits, which then fail to capture low developmental functioning once the mental age of the individual drops below the basal age of the assessment tool. Yet, metrics to measure disease progression are essential to inform therapeutic decision-making, prognostication, and clinical trial outcomes.